Lambrolizumab;Pembrolizumab;pembrolimumab;Pembrolizumab (anti-PD-1);PEMBROLIMUMAB PD-1 1374853-91-4;Pembrolizumab 25mg/ml;PembrolizumabQ: What is
Pembrolizumab Q: What is the CAS Number of
Pembrolizumab Q: What is the storage condition of
Pembrolizumab Q: What are the applications of
Pembrolizumab;Research Grade Pembrolizumab(DHH02202)
Pembrolizumab is indicated for: (1) unresectable or metastatic melanoma, including cases with disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor; (2) metastatic non-small cell lung cancer (NSCLC) as determined by an FDA-approved test, in patients whose disease has progressed on or after platinum-containing chemotherapy, and who do not have EGFR or ALK genomic tumor aberrations or have progressed on FDA-approved therapy for these aberrations; (3) treatment of other advanced solid tumors and hematologic malignancies, demonstrating antitumor activity with an acceptable safety profile. It functions as an immune checkpoint inhibitor by selectively blocking the PD-1 receptor, thereby enhancing antitumor immune responses.